Gavin Yamey , Kaci Kennedy McDade , Roy M. Anderson , Sarah M. Bartsch , Maria Elena Bottazzi , David Diemert , Peter J. Hotez , Bruce Y. Lee , Donald McManus , Adebayo J. Molehin , Meta Roestenberg , David Rollinson , Afzal A. Siddiqui , Miriam Tendler , Joanne P. Webster , Hong You , Raphaël M. Zellweger , Caroline Marshall
{"title":"Vaccine value profile for schistosomiasis","authors":"Gavin Yamey , Kaci Kennedy McDade , Roy M. Anderson , Sarah M. Bartsch , Maria Elena Bottazzi , David Diemert , Peter J. Hotez , Bruce Y. Lee , Donald McManus , Adebayo J. Molehin , Meta Roestenberg , David Rollinson , Afzal A. Siddiqui , Miriam Tendler , Joanne P. Webster , Hong You , Raphaël M. Zellweger , Caroline Marshall","doi":"10.1016/j.vaccine.2024.05.068","DOIUrl":null,"url":null,"abstract":"<div><div>Schistosomiasis is caused by parasitic flatworms (<em>Schistosoma</em>). The disease in humans can be caused by seven different species of <em>Schistosoma</em>: <em>S. mansoni</em>, <em>S. japonicum, S. haematobium, S. malayensis, S. mekongi, S. guineensis</em> and <em>S. intercalatum</em>, as well as by hybrids between species, including livestock schistosome species. People are infected when exposed to infested water and the parasite larvae penetrate the skin. Poor and rural communities are typically the most affected, and the general population who lives in affected areas and is exposed to contaminated water is at risk. Areas with poor access to safe water and adequate sanitation are also at heightened risk. About 236.6 million people required treatment for schistosomiasis in 2019—mostly people living in poor, rural communities, especially fishing and agricultural communities.</div><div>This ‘Vaccine Value Profile’ (VVP) for schistosomiasis is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the schistosomiasis VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"64 ","pages":"Article 126020"},"PeriodicalIF":4.5000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24006455","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Schistosomiasis is caused by parasitic flatworms (Schistosoma). The disease in humans can be caused by seven different species of Schistosoma: S. mansoni, S. japonicum, S. haematobium, S. malayensis, S. mekongi, S. guineensis and S. intercalatum, as well as by hybrids between species, including livestock schistosome species. People are infected when exposed to infested water and the parasite larvae penetrate the skin. Poor and rural communities are typically the most affected, and the general population who lives in affected areas and is exposed to contaminated water is at risk. Areas with poor access to safe water and adequate sanitation are also at heightened risk. About 236.6 million people required treatment for schistosomiasis in 2019—mostly people living in poor, rural communities, especially fishing and agricultural communities.
This ‘Vaccine Value Profile’ (VVP) for schistosomiasis is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the schistosomiasis VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.